Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance

BMC Infectious Diseases

Oumar Gaye¹  Léon Amath Ndiaye¹  Kuaku Folly¹  Aminata Colé LO¹  Magatte Ndiaye¹  Jean Louis Ndiaye¹  Doudou Sow¹  Babacar Faye¹  Roger Clément Kouly Tine¹  Annie Abiola¹  Khadime Sylla¹ 

[1] Département de Parasitologie-Mycologie, Faculté de Médecine, Université Cheikh Anta DIOP de Dakar, Dakar, Senegal

关键词: Senegal;    Plasmodium falciparum;    Malaria;    Artemisinin combination therapy;   

Others  :  1135746
DOI  :  10.1186/1471-2334-13-598

 received in 2013-05-08, accepted in 2013-12-10,  发布年份 2013

【 摘 要 】

Background

Malaria remains a major public health problem in developing countries. Then in these countries prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations for the Senegalese national malaria control program.

Methods

An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to assess the efficacy and safety of three combinations: dihydro-artemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO’s protocol for antimalarial drug evaluation was used to assess each outcome.

Results

Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ (n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety profile was noted in the 3 study groups.

Conclusion

In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs. However, it’s remains important to continue to monitor their efficacy.

Trial registration

PACTR 201305000552290.

【 授权许可】

   
2013 Sylla et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization: World malaria report. ISBN; 2011. 978 92 4 156440 3
• [2]World Health Organization: Guidelines for the treatment of Malaria. Geneva, Switzerland; 2006.
• [3]World Health Organization: Antimalarial drug combination therapy: Report of a WHO Technical Consultation. Geneva, Switzerland: WHO Press; 2001.
• [4]World Health Organization: Guidelines for the treatment of malaria. 2nd edition. Geneva: WHO Press; 2010.
• [5]Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, Diallo I, Ba F, Ndiaye JL, Albertini A, Lee E, Jorgensen P, Gaye O, Bell D: Major reduction in anti-malarial drug consumption in senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS One 2011, 6:4.
• [6]National malaria control program Senegal: Strategic plan against malaria, Ministry of Health Senegal 2006–2010.
• [7]Dondor AM, Nosten F, Yi P, Da D, Phyo A, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Imwong , Chotivanich K, Lim P, Herdman T, Sam An S, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med 2009, 361:455-467.
• [8]World Health Organization: Global Malaria Programme: Update on artemisinin resistance. 2012.
• [9]Thiam S, Ndiaye JL, Diallo I, Gatonga P, Fall FB, Diallo NE, Faye B, Diouf ML, Ndiop M, Diouf MB, et al.: Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting. Malar J 2013, 12:54. 10.1186/1475-2875-12-54 BioMed Central Full Text
• [10]World Health Organization: Evaluation et surveillance de l’efficacité des antipaludiques pour le traitement du paludisme non compliqué à. Plasmodium FalciparumWHO/HTM/RBM/2003.50
• [11]Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G: The use of genotyping in anti-malarial clinical trials: a systematic review of published studies from 1995–2005. Malar J 2006, 5:122. BioMed Central Full Text
• [12]Faye B, NDiaye JL, Dieng Y, Faye O, Gaye O: Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J 2006, 6:80.
• [13]Tine RCK, Faye B, Sylla K, Ndiaye JL, Ndiaye M, Sow D, Lo AC, Abiola A, Ba MC, Gaye O: Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial. Malar J 2012, 11:416. BioMed Central Full Text
• [14]Faye B, Offianan AT, Ndiaye JL, Tine RC, Toure W, Djoman K, Sylla K, Ndiaye PS, Penali L, Gaye O: Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med and Int Health 2010, 15:608-613.
• [15]Menan H, Faye O, Ekobo SA, Oga SA, Faye B, Barro CPK, Kuete T, N’diaye JL, Vicky AM, Tine R, Yavo W, Kane K, Kassi KF, Kone M: Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine – trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar J 2011, 10:185. BioMed Central Full Text
• [16]Makanga M, Krudsood S: Clinical efficacy of artemether/lumefantrine (Coartem). Malar J 2009, 8:55. BioMed Central Full Text
• [17]Faye B, Kuété T, Barro CPK, Tine RC, Nkoa T, Ndiaye JL, Kakpo CA, Sylla K, Menan H, Gaye O, Faye O, Ekobo AS, Koné M: Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J 2012, 11:433. BioMed Central Full Text
• [18]Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Ekobo AS, Gaye O: Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009, 8:25. BioMed Central Full Text
• [19]Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, Brasseur P: Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar J 2013, 12:53. BioMed Central Full Text
• [20]Zwang J, Olliaro P, Barennes PH, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D’Alessandro U, Djimdé A, Karema C, Guthmann JP, Hamour S, Ndiaye JL, Martensson A, Rwagacondo C, Sagara I, Ekobo AS, Sirima SB, van den Broek I, Yeka A, Taylor WRJ, Dorsey G, Randrianarivelojosia M: Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009, 8:203. BioMed Central Full Text
• [21]Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi R, Diatta M, Ama MV, Tine R, Ndiaye JL, Evi1 JB, Ekobo AS, Faye O, Koné M: Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J 2011, 10:198. BioMed Central Full Text
• [22]Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NL: Randomized, controlled dose-optimization studies of Dihydroartemisinin-Piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. JID 2004, 190(10):1773-1782.
• [23]Thanh XT, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, Chavchich M, Edstein MD: The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate amodiaquine (Coarsucam) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J 2012, 11:217. BioMed Central Full Text
• [24]Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokunthea S, Sophorn L, Zhou C, Deng C, Wang Q, Guoqiao L: Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 2011, 10:231. BioMed Central Full Text
• [25]Gargano N, Ubben D, Tommasini S, Bacchieri A, Corsi M, Bhattacharyya PC, Rao BHK, Dubashi N, Dev V, Ghosh SK, Kumar A, Srivastava B, Valecha N: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malar J 2012, 11:233. BioMed Central Full Text
• [26]Grande T, Bernasconi A, Erhart A, Gamboa D, Martin Casapia M, Delgado C, Torres K, Fanello C, Llanos-Cuentas A, D’Alessandro U: A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru. PLoS One 2007, 10:1101. 10.1371
• [27]Zwang J, Ashley EA, Karema C, D’Alessandro U, Smithuis F, Dorsey G, Janssens B, Mayxay M, Newton P, Singhasivanon P, Stepniewska K, White NJ, Nosten F: Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009, 4:7.
• [28]Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM: Therapeutic Efficacies of Artemisinin-Based Combination Therapies in Nigerian Children with uncomplicated Falciparum Malaria during Five years of adoption as first-Line treatments. Am J Trop Med Hyg 2011, 84(6):936-939.
• [29]Olliaro P, Djimdé A, Dorsey G, Karema C, Martensson A, Ndiaye JL, Sirima SB, Vaillant M, Zwang J: Hematologic Parameters in Pediatric Uncomplicated Plasmodium falciparum Malaria in Sub-Saharan Africa. Am J Trop Med Hyg 2011, 85(4):619-625.
• [30]Price RN, Simpson JA, Nosten F, Luxemburger L, Hkirjaroen L, feiko ter Kuile FT, Chongsuphajaisiddhi T, white NJ: Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 2001, 65(5):614-622.
• [31]Zwang J, Ndiaye JL, Djimde A, Dorsey G, Martensson A, Karema C, Olliaro P: Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J 2012, 11:25. BioMed Central Full Text
• [32]Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, Hutagalung R, Singtoroj , Hla G, Brockman AI, Proux S, Wilahphaingern J, Singhasivanon S, White NJ, Nosten F: Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med and Int Health 2010, 15:608-613. 2007; 12; 201–208
• [33]Mayxay M, Khanthavong M, Chanthongthip O, Imwong M, Pongvongs T, Hongvanthong B, Phompida S, Vanisaveth V, White NJ, Newton PN: Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos. Malar J 2012, 11:184. BioMed Central Full Text